Introduction {#Sec1}
============

The identification of the "transactive response (TAR) DNA-binding protein-43" (TDP-43) as the main component of the pathological lesions in patients with frontotemporal lobar degeneration (FTLD) with ubiquitin-positive inclusions, in those with amyotrophic lateral sclerosis (ALS), and in FTLD with motoneuron disease (FTLD-MND) provided strong support to the contention that these seemingly different diseases represent different parts of one neurodegenerative spectrum \[[@CR1]\]. Soon thereafter, missense mutations in the gene encoding the TDP-43 protein (*TARDBP*) were identified in patients with autosomal dominant ALS \[[@CR2], [@CR3]\] and, albeit more rarely, in patients with FTLD with or without ALS \[[@CR4]--[@CR6]\], demonstrating a primary, causal role for the TDP-43 protein abnormalities in the pathogenesis of these diseases, now also termed TDP-43 proteinopathies \[[@CR7]\]. The function of the TDP-43 protein remains poorly understood, but it has been initially characterized as a transcription factor which binds to TAR DNA sequence motif \[[@CR8]\] and, later, as a modulator of the alternative mRNA splicing \[[@CR9]\].

Several *TARDBP* mutations have been identified in patients with familial and also sporadic ALS, these latter pointing to an incomplete, age-related penetrance \[[@CR10]--[@CR17]\]. The c.G1144A substitution (predicted protein effect: p.Ala382Thr) is the most frequent *TARDBP* mutation known so far, which has been found in ALS patients of Italian and French origins \[[@CR3], [@CR15], [@CR16]\]. Very recently, the same missense mutation was identified as the disease cause in a large percentage (\~30%) of familial and sporadic ALS patients from Sardinia, a genetically isolated Mediterranean island \[[@CR18], [@CR19]\]. Haplotype analyses in the Sardinian, Italian, and French cases strongly suggested that this mutation originated from a common founder \[[@CR15], [@CR18], [@CR19]\].

The occurrence of parkinsonism and motoneuron disease in the same patient has sometimes been reported \[[@CR20]\]. Of note, three Sardinian patients with ALS who carried the *TARDBP* p.Ala382Thr mutation developed parkinsonism after the onset of the motoneuron disease \[[@CR18]\]. However, to our knowledge, *TARDBP* mutations have not been described in patients with Parkinson's disease (PD).

As part of an ongoing research program on the genetics of PD in Sardinia, we therefore investigated the occurrence of the *TARDBP* p.Ala382Thr mutation among patients with this disease from this genetically isolated population. We detected 8 out of the 327 PD cases (2.5%) who are carriers of this mutation. Our data provide therefore a first direct link between the *TARDBP* mutation and PD, supporting an involvement of the TDP-43 protein in a broader neurodegenerative spectrum, including not only motoneuron disease and FTLD, but also PD.

Subjects and methods {#Sec2}
====================

All cases and controls included in the study (905 subjects) were born and living in Sardinia, and all their four grandparents were also born in Sardinia. The project was approved by the relevant ethical authorities and written informed consent was obtained from all participating subjects.

The PD group included 327 consecutive patients (125 females, 202 males) with clinically diagnosed PD, recruited at two movement disorder units in southern central areas of Sardinia: the General Hospital "S. Michele" in Cagliari (301 patients) and the S. Francesco Hospital in Nuoro (26 patients). The average onset age was 62.6 years (SD 10.5, range 22--84). Additional clinical features are shown in Table [1](#Tab1){ref-type="table"}. All patients fulfilled the United Kingdom Brain Bank Criteria for the clinical diagnosis of PD \[[@CR21]\]. No pathological studies were available. A detailed medical history of the nuclear family was recorded from all the PD cases. Patients were classified as sporadic if they reported no other PD cases among first- and second-degree relatives. Accordingly, there were 88 patients with familial and 239 with sporadic PD presentation. The clinical evaluation of the parkinsonism was performed using the Hoehn-Yahr Scale and the Unified Parkinson's Disease Rating Scale (UPDRS) \[[@CR22]\]. The Mini-Mental State Examination (MMSE) was used as a screening test for the cognitive status. Table 1Clinical features in the PD seriesp.Ala382ThrHet carriersNon-carriersTotal no. of patients8319Males7195Females1124Familial PD088Sporadic PD8231PD onset age, years \[average (SD)\]70.0 (9.4)62.9 (10.5)

One family with three siblings affected by different combinations of atypical parkinsonism, FTLD, and [l]{.smallcaps}-dopa-responsive parkinsonism was also ascertained and studied (Fig. [1](#Fig1){ref-type="fig"}). A first control group consisted of 203 subjects, age-matched to the patients (86 females, 117 males), mainly spouses of PD cases or subjects examined at the same centers for diseases unrelated to PD. The average age at sampling was 71.3 years (SD 10.8, range 38--93). Among these, 174 were collected in Cagliari and 29 in Nuoro. Controls were eligible for inclusion only if they reported a negative family history of PD among first- and second-degree relatives. Moreover, at the time of the examination, none of the controls showed any signs or symptoms of parkinsonism, dementia, motoneuron disease or other neurodegenerative diseases. Fig. 1Genetic findings and neuroimaging in a family with FTLD with parkinsonism and PD. **a** Pedigree of the family. **b** Electropherogram showing the heterozygous *TARDBP* p.Ala382Thr mutation. **c** DaTSCAN-SPECT in the SAR-403 patient showing severe defects at the level of the caudate nucleus and putamen, bilaterally

A second, younger group of controls was available, consisting of 375 healthy subjects (92 females, 283 males) ascertained within a research program on the genetics of multiple sclerosis in Sardinia \[[@CR23]\]. The average age at sampling of this second control group was 42.8 years (SD 10.6, range 21--66).

Genomic DNA was isolated from peripheral blood using standard protocols. In the whole case--control sample, the presence of the *TARDBP* c.G1144A mutation (p.Ala382Thr) was assessed by direct DNA sequencing. In patients who carried this mutation and in additional selected patients with familial PD, the whole *TARDBP* coding region and exon--intron boundaries was sequenced. In all cases with the *TARDBP* p.Ala382Thr mutation, we also searched for the *LRRK2* p.Gly2019Ser mutation (previously reported to occur, albeit rarely, among Sardinian PD patients) \[[@CR24]\] by direct sequencing, as previously described \[[@CR24]\].

Fragments were amplified by PCR (protocols and primers available on request from the authors). Direct sequencing was performed using Big Dye terminator chemistry ver.3.1 (Applied Biosystem). Fragments were loaded on an Applied Biosystem 3130XL automated sequencer and analyzed with DNA Sequencing analysis (ver.5.3) and SeqScape (ver.2.6) software (Applied Biosystem). The *TARDBP* mutation is numbered from the "A" of the ATG-translation initiation codon, according to GenBank reference sequences, accession number NM_007375.3.

Results {#Sec3}
=======

We identified 8 PD cases who carried the *TARDBP* c.G1144A (p.Ala382Thr) variant in heterozygous state (8/327, 2.5%) and no homozygous carriers. The detailed clinical features in the patients who carried the p.Ala382Thr mutation are shown in Table [2](#Tab2){ref-type="table"}. Sequencing the whole *TARDBP* coding region and exon--intron boundaries in patients with the p.Ala382Thr mutation, as well as in five additional patients with familial PD revealed no additional novel variants. No carriers of the *LRRK2* Gly2019Ser mutation were detected. Table 2Clinical features in the PD patients carrying the *TARDBP* p.Ala382Thr mutationPatientFamilial/sporadicAge (years)GenderPD onset (years)Disease duration (years)Initial symptoms (asymmetry)[l]{.smallcaps}-dopa resp.DaTSCANSupportive non-motor symptomsMMSE scoreSar-006Sporadic86M797RT, B, R (right)Sustainedn.p.Hyposmia24/30Sar-053Sporadic65M5114RT (right)Sustainedn.p.RBD30/30Sar-104Sporadic71M656RT, B, R (right)SustainedTypical for PDRBD, hyposmia27/30Sar-146Sporadic84M786RT, B, R (right)Sustainedn.p.RBD, hyposmia23/30Sar-171Sporadic80M755RT, B, R (right) mild cognitive decline+n.p.−18/30Sar-220Sporadic91M7120B, R (right)+n.p.−22/30Sar-239Sporadic71F656RT, B, R (right)SustainedTypical for PDRBD29/30Sar-579Sporadic81M765RT, B, R (left) mild cognitive decline+n.p.−20/30*M* male, *F* female, *RT* rest tremor, *B* bradykinesia, *R* rigidity, *MMSE* Mini-Mental State Examination, *n.p.* not performed, *RBD* REM-sleep behavior disorder, *+* present, *−* absent

Within the first group of controls, we identified three subjects who also carried the p.Ala382Thr mutation in heterozygous state and none who carried it in homozygous state. Within the second group of controls, no mutation carriers were detected. Our follow-up revealed that one of the three heterozygous mutation carriers had developed motoneuron disease at age 61, 2 years after sampling; another developed a rapidly progressive dementia starting approximately at age 81, 1 year after sampling, and he has became bedridden, anarthric, and totally dependent from caregivers' assistance within 4 years of disease evolution. The third subject remains free from signs or symptoms of motoneuron disease, dementia, or parkinsonism at the age of 79, but two of his close relatives have recently developed motoneuron disease and dementia. If one excludes these three control subjects who developed motoneuron disease, or dementia, or who had close relatives with these diseases, none of the 575 Sardinian controls in this study (1,150 chromosomes) carry the p.Ala382Thr mutation. Furthermore, in previous studies, this mutation was not detected in more than 500 Sardinian control chromosomes \[[@CR18], [@CR19]\] and in more than 1,900 Italian control chromosomes \[[@CR15], [@CR16]\].

None of the eight PD patients who carried the p.Ala382Thr mutation reported any first- or second-degree relatives affected by PD, dementia, or motoneuron disease. They are therefore classified as sporadic PD according to our criteria. However, information on parental age at death was available for only six of the eight mutation carrier probands (Table [3](#Tab3){ref-type="table"}). Considering the late onset age of PD in these cases and the parental age at death, censoring effects might have masked the familial nature of the disease in at least some of these cases. Furthermore, two patients (Sar-006 and Sar-104) reported each one more distant relative (first cousin) with parkinsonism. Our examination of these distant relatives revealed in both cases a late onset, atypical parkinsonism with poor response to levodopa, and genetic testing revealed absence of the p.Ala382Thr mutation. We consider these two distant relatives as phenocopies. Table 3Age at death among the parents of PD patients carrying the p.Ala382Thr mutationPD patientMotherFatherPD onset in offspringSar-006858079Sar-053n.a.n.a.51Sar-10472^a^8465Sar-146809078Sar-171833075Sar-220n.a.n.a.71Sar-239646465Sar-579876076^a^Referred with tremor

The eight patients who carried the p.Ala382Thr mutation all fulfilled the UK PD Society Brain Bank criteria for a clinical diagnosis of definite PD. Six of these display a classical PD presentation (Table [2](#Tab2){ref-type="table"}), while two (Sar-171 and Sar-579) present with a postural instability--gait disturbance predominant type of PD and also have mild cognitive impairment and psychotic phenomena.

The average PD symptoms onset in the eight carriers of the p.Ala382Thr mutation was 70.0 ± 9.4 years (range 51--79), which is later though not significantly different from the average onset age among the patients who did not carry this mutation (62.9 ± 10.5 years, range 22--83, *p* = 0.08). Brain SPECT images (DaTSCAN) were available from two patients with the p.Ala382Thr mutation and are shown in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2DaTSCAN-SPECT images in PD patients with the *TARDBP* p.Ala382Thr mutation. In two patients carrying the *TARDBP* p.Ala382Thr mutation (**a** Sar-239, **b** Sar-104), the DaTSCAN-SPECT imaging shows asymmetric defects, predominantly at the level of the putamen, as typically observed in idiopathic PD

Within the FTLD--parkinsonism family (Fig. [1](#Fig1){ref-type="fig"}), three siblings were affected by different combinations of atypical parkinsonism, FTLD, and [l]{.smallcaps}-dopa-responsive parkinsonism, and they all carried the p.Ala382Thr heterozygous mutation. The patients' mother died at the age of 74 and the father at the age of 54 (due to hepatic disease), without evidence of neurodegenerative diseases. The proband (Sar-403) is a 77-year-old, congenital deaf-mute woman, who developed resting tremor and bradykinesia in her right limbs and at the age of 76. At the moment of our examination, after 1 year of disease course, her H-Y stage was 1.5 and the UPDRS motor score 13. Only mild benefit was observed after 12 months of [l]{.smallcaps}-dopa treatment (daily dose of 500 mg, four times per day). Though her MMSE was 30/30, she developed hallucinations and mild cognitive disturbances of frontal lobe type. Brain CT scan was unremarkable, but DaTSCAN showed severe bilateral dopaminergic deficiency at the level of both putamen and caudate nuclei (Fig. [1c](#Fig1){ref-type="fig"}), suggestive of an atypical parkinsonian disorder. Of note, evidence of motoneuron disease was not detected after both clinical examination and EMG investigations, after 1 year of disease course.

The proband's brother (Sar-424) developed a rapidly progressive, symmetrical akinetic-rigid parkinsonism with onset at the age of 68 years, with only a mild response to [l]{.smallcaps}-dopa treatment (daily dose of 600 mg, four times per day). At the moment of our examination, after 2 years of disease course, his H-Y stage was 4, the UPDRS motor score was 54, and the MMSE was 28/30, but he also showed severe dementia of frontotemporal type. Frontotemporal atrophy was also seen in his brain MRI. He died 2 years later at the age of 72.

Interestingly, the proband's sister (Sar-423) developed symmetrical akinetic-rigid parkinsonism without resting tremor at the age of 74 years. At the moment of our examination, after 1 year of disease course, her H-Y stage was 2 and the UPDRS motor score 28. Her MMSE was 30/30. At that time, she responded well to [l]{.smallcaps}-dopa treatment and no atypical features or additional neurological signs were observed; her clinical picture was therefore compatible with a diagnosis of PD. She died 3 years later, at the age of 78, of acute myocardial infarction.

Discussion {#Sec4}
==========

Genetically isolated populations are an important resource for finding genetic determinants of human diseases. As a result of a limited number of founder alleles, prolonged geographical isolation, and genetic drift, the genetic architecture of disease is expected to be simpler in the genetic isolates than in the general populations, thereby facilitating the identification of the disease-causing or disease-predisposing alleles \[[@CR25]\]. The population of Sardinia is one of the most extensively studied genetic isolates, which has yielded founder mutations and risk alleles in several disorders (\[[@CR18], [@CR19], [@CR23], [@CR26]\] and references therein).

The recent identification of the founder *TARDBP* p.Ala382Thr mutation as the cause of a large percentage of ALS cases in this island is not only another example of the power of this approach. It is also a proof of principle that large etiological fractions of common neurodegenerative diseases can be underlain by rare mutations of large effects. A similar scenario has been delineated for the founder p.Gly2019Ser mutation in the *LRRK2* gene as a cause of PD among patients of North African and Middle Eastern ancestries (reviewed in \[[@CR27]\]).

The fact that all the three apparently healthy controls included in our study, who carried the p.Ala382Thr mutation, have developed ALS or dementia themselves or among their close relatives is a clear confirmation of the strong association between this mutation and the motoneuron disease--frontotemporal dementia spectrum. Furthermore, one control individual remains free from neurodegenerative signs and symptoms at the age of 79 years, illustrating the age-related, incomplete penetrance, already reported for this and other *TARDBP* mutations. A penetrance of 60% by age 70 has been recently estimated for the p.Ala382Thr mutation \[[@CR19]\]. The incomplete penetrance is also in keeping with the frequent occurrence of this founder mutation among patients with sporadic disease presentation.

While *TARDBP* mutations have been detected in several patients with familial and sporadic ALS (approximately 2--3% of cases in large studies), to our knowledge, an association between *TARDBP* mutations and FTLD has been reported so far in only eight unrelated cases \[[@CR4]--[@CR6], [@CR28], [@CR29]\]. In two of these patients, the FTLD phenotype (familial in one and sporadic in the other case) was followed by the development of MND within 2 years \[[@CR5]\]; in another three cases with familial ALS (and carrying the p.Ala382Thr mutation), the MND was the presenting phenotype, which was followed soon by an FTLD \[[@CR29]\]. In the remaining three patients, sporadic FTLD presented as an isolated syndrome, without the development of MND within the follow-up period \[[@CR4], [@CR6], [@CR28]\]. Of note, none of these cases presented parkinsonism.

Only three of the recently reported Sardinian ALS patients who carried the p.Ala382Thr mutation developed akinetic parkinsonism after the onset of ALS \[[@CR18]\]. Therefore, our family with FTLD and parkinsonism (Fig. [1](#Fig1){ref-type="fig"}) represents already a further expansion of the clinical spectrum associated with *TARDBP* mutations, by showing two patients with FTLD and prominent parkinsonism without MND, and a third with pure, [l]{.smallcaps}-dopa-responsive parkinsonism, in the absence of cognitive or motoneuron disturbances.

However, the most important finding of this study is the association between the p.Ala382Thr mutation and PD within our consecutive large Sardinian series. This points to a broader clinical expressivity of this mutation than earlier realized.

To our knowledge, only one systematic study of the entire *TARDBP* coding region in 125 PD patients of French--Canadian ancestry has been published, with negative results \[[@CR30]\]. It is interesting to note that none of our eight PD patients who carry the mutation reported a family history for PD, ALS, or dementia, providing further evidence for the incomplete penetrance of this mutation.

Unfortunately, pathological studies are not available to verify whether Lewy bodies, TDP-43-positive inclusions, or both, are present in the brain of these patients. This remains a very important objective for follow-up studies. However, all these eight cases fulfill the widely accepted clinical diagnostic criteria for definite PD, including several supporting features (asymmetric onset, good and prolonged [l]{.smallcaps}-dopa response, presence of resting tremor, progressive course with the absence of atypical signs for more than 5 years). In two patients carrying the *TARDBP* p.Ala382Thr mutation, the DaTSCAN-SPECT imaging showed asymmetric defects, predominantly at the level of the putamen, as typically observed in idiopathic PD (Fig. [2](#Fig2){ref-type="fig"}). Apart from a slightly (and non-significantly) later onset age of PD symptoms, these cases were clinically indistinguishable from the other patients in our study.

The reasons of the broad variability in the clinical expression of this mutation remain to be found. It is possible that the severity and the rapid progression of the ALS hamper the detection of extrapyramidal signs. However, three patients who carried the p.Ala382Thr mutation described in one of the previous studies developed extrapyramidal symptoms several years after their initial presentation with motoneuron disease \[[@CR18]\]. On the other hand, it is possible that the clinical signs of PD interfere with the detection of initial motoneuron disease signs. Nevertheless, none of our PD mutation carriers nor any of their close relatives developed clinical signs of the ALS spectrum.

It is likely that additional genetic (or non-genetic) factors modify the effects of the primary mutation (p.Ala382Thr), thereby leading to different clinical outcomes: ALS, FTLD, or parkinsonism, alone or in combination. For example, patients who manifest PD, or FTLD, as the resulting isolated clinical phenotype might carry mutations or polymorphisms in other loci that prevent (or delay) the onset of motoneuron disease and lead to the appearance of extrapyramidal or cognitive signs as the earliest clinical expression of the disease. Further work remains therefore ahead to identify the modifier(s) of this mutation, and genetic isolates (such as the Sardinian population) represent once more an ideal resource in this endeavor.

Following the initial association with the pathological hallmark inclusions in patients with FTLD, ALS, and ALS-MND, the TDP-43 protein has also been detected in the pathological lesions in relevant percentages of brains of patients with Lewy body disorders, ranging from 7% of PD cases to 19% of PD with dementia in one study \[[@CR31]\], and to more than 50% of the brains with diffuse Lewy body disease in another study \[[@CR32]\]. Moreover, pathological lesions containing the TDP-43 protein were reported in proximity of small blood vessels in the brain of one patient with familial Lewy body disease caused by the p.Ala53Thr mutation in the *alpha-synuclein* (*SNCA*) gene \[[@CR33]\]. Taken together, these findings provide evidences of important intersections between the pathogenesis of the TDP-43 proteinopathies and the alpha-synucleinopathies, supporting the contention that *TARDBP* mutations might underlie prominent parkinsonism in patients with FTLD and also present as isolated PD.

In conclusion, our data provide a first direct link between the *TARDBP* mutation and PD, supporting an involvement of the TDP-43 protein in a broader neurodegenerative spectrum, including not only motoneuron disease and FTLD, but also PD. Further analyses of the whole *TARDBP* coding region in large series of familial and sporadic PD patients are warranted.
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